Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NRAS wild-type||colorectal cancer||predicted - sensitive||Panitumumab||Phase III||Actionable||In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).||26341920|
|NRAS wild-type||colorectal cancer||predicted - sensitive||Panitumumab||FDA approved - On Companion Diagnostic||Actionable||Vectibix (panitumumab) is FDA approved for metastatic colorectal patients that are NRAS wild-type, as detected by a companion diagnostic (FDA.gov).||detail... detail...|
|PubMed Id||Reference Title||Details|
|(26341920)||Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.||Full reference...|
|Vectibix (panitumumab) FDA Drug Label||Full reference...|